KALA BIO (KALA)

• Market cap: $44.4M
• 1 day: 8.64%
• 5 days: 11.16%
• 1 month: -55.74%
• 3 months: -87.68%
• 6 months: -95.65%
• Year to date: -92.31%
• 1 year: -98.64%
• 5 years: -99.98%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Employees: 6